米吉珠单抗治疗银屑病的疗效与安全性:一项52周、双盲、安慰剂对照、随机撤药、III期试验(OASIS-1)结果
OASIS-1是一项双盲、安慰剂对照、随机撤药III期试验,纳入530例中重度斑块状银屑病患者,按4:1随机接受米吉珠单抗250 mg或安慰剂每4周皮下注射至第16周。第16周米吉珠单抗组sPGA(0,1)应答69.3% vs 安慰剂6.5%,PASI 90应答64.3% vs 6.5%(均P<0.001)。应答者再随机分组至第52周,米吉珠单抗250 mg每8周或125 mg每8周维持疗效且安全性良好,换用安慰剂者疗效逐渐丧失。
要点
- 第16周米吉珠单抗sPGA(0,1)应答69.3% vs 安慰剂6.5%,PASI 90应答64.3% vs 6.5%。
- 第52周米吉珠单抗250Q4W/250Q8W组PASI 90应答86%、PASI 100应答60%、sPGA(0,1)应答82%。
- 严重不良事件发生率诱导期米吉珠单抗1.2% vs 安慰剂1.9%,维持期相似,无死亡。
核心结论
- 米吉珠单抗在第16周优于安慰剂,并维持疗效至第52周,未发现新的安全性信号。
研究设计与样本
- OASIS-1(NCT03482011)为双盲、安慰剂对照、随机撤药III期试验,纳入530例中重度斑块状银屑病患者,按4:1随机接受米吉珠单抗250 mg或安慰剂每4周皮下注射至第16周。
主要发现
- 第16周sPGA(0,1)应答米吉珠单抗组293/423(69.3%)vs 安慰剂组7/107(6.5%),P<0.001。
- 第16周PASI 90应答米吉珠单抗组272/423(64.3%)vs 安慰剂组7/107(6.5%),P<0.001。
- 第16周PASI 75应答米吉珠单抗组349例(82.5%)vs 安慰剂组10例(9.3%),PASI 100应答米吉珠单抗组137例(32.4%)vs 安慰剂组1例(0.9%),均P<0.001。
- 第52周PASI 90、PASI 100、sPGA(0,1)应答分别为:米吉珠单抗250Q4W/安慰剂Q8W组(N=91)19%、10%、18%;米吉珠单抗250Q4W/125Q8W组(N=90)86%、59%、86%;米吉珠单抗250Q4W/250Q8W组(N=91)86%、60%、82%;均P<0.001。
- 严重不良事件发生率:诱导期米吉珠单抗1.2% vs 安慰剂1.9%;维持期米吉珠单抗250Q4W/125Q8W组1%、米吉珠单抗250Q4W/250Q8W组3% vs 安慰剂3%;无死亡。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interleukin-23 inhibitors are effective and safe for treating moderate-to-severe plaque psoriasis. OBJECTIVES: To evaluate the efficacy and safety of mirikizumab in adult patients with moderate-to-severe plaque psoriasis through 52 weeks in a phase III randomized controlled trial. METHODS: OASIS-1 (NCT03482011) was a double-blind, placebo-controlled, randomized withdrawal, phase III trial. Patients (n = 530, randomized 4 : 1) received subcutaneous mirikizumab 250 mg or placebo every 4 weeks (Q4W) through week 16. Coprimary endpoints were superiority of mirikizumab vs. placebo on static Physician's Global Assessment (sPGA; score of 0 or 1 with ≥ 2-point improvement) and ≥ 90% improvement in Psoriasis Area and Severity Index (PASI 90, responders) at week 16. Mirikizumab responders were rerandomized (1 : 1 : 1) to mirikizumab 250 mg every 8 weeks (Q8W), mirikizumab 125 mg Q8W, or placebo Q8W through week 52. Secondary endpoints were evaluated at weeks 16 and 52. Safety was monitored in all patients. RESULTS: All primary and key secondary endpoints were met. At week 16, sPGA(0,1) responses were significantly greater with mirikizumab (293 of 423, 69·3%) than placebo (seven of 107, 6·5%) (P < 0·001). PASI 90 response was also greater with mirikizumab (272 of 423, 64·3%) than placebo (seven of 107, 6·5%) (P < 0·001). Significantly more patients in the mirikizumab arms achieved PASI 75 and PASI 100 (mirikizumab 349, 82·5% and 137, 32·4%; placebo 10, 9·3% and 1, 0·9%, respectively; all P < 0·001). At week 52, PASI 90, PASI 100 and sPGA(0,1) responses were mirikizumab 250Q4W/placeboQ8W (N = 91; 19%, 10%, 18%), mirikizumab 250Q4W/125Q8W (N = 90; 86%, 59%, 86%) and mirikizumab 250Q4W/250Q8W (N = 91; 86%, 60%, 82%; all P < 0·001), respectively. Rates of serious adverse events were similar across treatments (induction: mirikizumab 1·2% vs. placebo 1·9%; maintenance: mirikizumab 250Q4W/125Q8W 1%, mirikizumab 250Q4W/250Q8W 3% vs. placebo 3%). No deaths occurred. CONCLUSIONS: Mirikizumab was superior to placebo at week 16 and maintained efficacy through week 52, with no new safety signals. What is already known about this topic? Interleukin (IL)-23 is a key cytokine in the pathogenesis of psoriasis. Drugs targeting the p19 subunit of IL-23 have recently been approved for the treatment of adult patients with moderate-to-severe plaque psoriasis. Patients with moderate-to-severe plaque psoriasis achieved significantly greater improvements in skin measures and patient-reported quality-of-life measures after 16 weeks when treated every 8 weeks with mirikizumab compared with placebo in a phase II clinical trial. What does this study add? Compared with placebo, mirikizumab demonstrated high levels of efficacy at week 16 in a large phase III trial; safety profiles were similar between the mirikizumab and placebo arms. After week 16, patients maintained on doses of mirikizumab 250 mg every 8 weeks (Q8W) or 125 mg Q8W showed similar efficacy and favourable safety profiles over 52 weeks, whereas patients switched to placebo gradually lost efficacy over time.
引用
- Blauvelt A, Kimball AB, Augustin M, et al. Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1). Br J Dermatol. 2022. PMID: 35791755. doi:10.1111/bjd.21743
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。